Asthma affects an estimated 300 million persons worldwide and is characterized by symptoms of cough, wheeze, chest tightness, and shortness of breath. Current dogma suggests asthma symptoms arise as a consequence of airway narrowing, bronchial hyperresponsiveness, and airway inflammation. Yet despite effective treatments targeting each of these components of asthma, many patients have substantial residual symptoms. Even in a clinical trial setting with optimal inhaled treatment, up to 50% of asthmatic patients have symptoms that are not well controlled. 1 Although for some patients adherence might be an issue, 2 it is also likely that undiscovered mechanisms explain the heterogeneity in asthma clinical phenotypes and treatment responses.
Symptoms are often challenging to study because they can only be reported subjectively; however, cough is readily amenable to objective quantification. 3 Cough in asthmatic patients is not only a common 4 and troublesome 5 symptom but also predicts disease severity 6 and poor prognosis, 7 suggesting it reflects important pathophysiologic processes, yet remarkably little is understood about the underlying mechanisms. The general assumption is that airway afferent nerves activating the cough reflex are stimulated by inflammatory mediators, mucus, and bronchospasm, and the possibility that these neuronal pathways are dysfunctional is rarely considered.
Vagal afferent fibers innervate the airways and are responsible for mediating symptoms and airway reflexes. 8, 9 Coughing is readily evoked by activation of C fibers; these networks of unmyelinated and chemically sensitive afferents are characteristically sensitive to capsaicin (chili pepper extract) through activation of the transient receptor potential vanilloid type 1 (TRPV1) channel. Ad fibers are sparsely distributed, thinly myelinated fibers in the proximal airways that also evoke cough. They protect the airways by responding to mechanical stimuli (eg, foreign objects) and changes in osmolarity and acidity. Importantly, they are typically insensitive to capsaicin and inflammatory mediators and do not usually express TRPV1.
Experimentally evoked cough responses to inhaled irritants are an established tool for studying the cough reflex and thus airway nerve function. Capsaicin is the most widely used agent, and the concentration of capsaicin causing 5 or more coughs (C5) is considered a measure of cough reflex sensitivity. 3 However, previous studies in asthmatic patients have produced conflicting results, with some studies suggesting sensitization of the cough reflex (reduced C5) and others finding no difference from healthy control subjects. [10] [11] [12] [13] We have recently investigated capsaicin-evoked cough responses using repeat inhalations of capsaicin and concentrations beyond C5. Nonlinear mixed-effects modeling of these data found maximum cough response evoked by any concentration of capsaicin (E max ) best discriminated patients with chronic cough from healthy control subjects/patients with mild asthma; the difference between healthy and asthmatic subjects did not quite reach a priori statistical significance.
14 Therefore we have studied capsaicin-evoked cough responses in a larger group of patients with well-characterized mild-to-moderate asthma and healthy volunteers. We also investigated the influence of sex, atopic status, lung physiology, inflammation, and asthma control on capsaicin-evoked cough responses. Some of the results of these studies have been previously reported in the form an abstract. 15, 16 
METHODS Subjects
Subjects with a physician's diagnosis of asthma were recruited but not selected for symptoms of cough. Treatment with salbutamol as required and/or inhaled corticosteroids at 500 mg or less of fluticasone propionate equivalent daily with or without a long-acting bronchodilator was permitted. Subjects with uncontrolled symptoms according to Global Initiative for Asthma classification or not receiving stable medication over the previous 4 weeks were excluded. Healthy control subjects approximately matched for age were also recruited. We excluded current smokers, those with a recent chest infection or exacerbation, and those using any medication that might alter the cough responses (eg, opiates, gabapentin, anticholinergics, and theophylline). The study protocols for healthy control subjects and asthmatic patients were approved by the local research ethics committee (13/COA/002 and 13/CLU/ 001), and all subjects provided written informed consent.
Study protocol and procedures
For full details, see the Methods section in this article's Online Repository at www.jacionline.org. Asthmatic patients attended on 3 occasions. On visit 1, subjects underwent history and examination and completed the Asthma Control Questionnaire (ACQ), Leicester Cough Questionnaire (LCQ), fraction of exhaled nitric oxide measurement (FENO; NIOX, Aerocrine, Solna, Sweden), spirometry, and bronchodilator reversibility measurement, and an ambulatory cough monitor (VitaloJAK; Vitalograph, Buckinghamshire, United Kingdom) was fitted for the next 24 hours. At visit 2, at least 48 hours later, subjects underwent full blood count, serum IgE measurement, skin prick testing, and PC 20 measurement. Subjects completed a peak flow diary twice a day for 7 days after visit 2.
Visit 3 took place at least 1 week later, and a capsaicin cough challenge was performed, as previously described, 14 by using a dosimeter (KoKo Dosimeter; Ferraris, Hertford, United Kingdom) and a nebulizer pot (Model 646; Devilbiss Healthcare, Somerset, Pa) with an inspiratory flow limiter. Briefly, 4 inhalations were administered, 30 seconds apart, of doubling doses of capsaicin (0.48-1000 mmol/L). After each inhalation, the number of coughs in the first 15 seconds was counted and later verified by using a cough monitor (VitaloJAK). The challenge was completed when the patient reached the final dose or the maximal tolerated dose. Spirometry was performed before and after each challenge.
Healthy volunteers attended on 2 occasions. On visit 1, consent was obtained, screening and spirometry were performed, and the ambulatory cough monitor was attached. On visit 2, the capsaicin challenge was performed.
Statistical analysis
Cough responses to capsaicin were analyzed by using nonlinear mixedeffects modeling software (NONMEM 7.3; ICON Development Solutions, Ellicott City, Md) and the Laplace estimation method. 17, 18 Additional investigations of the NONMEM output and statistical and graphic analyses were performed in Matlab R2014a (MathWorks, Natick, Mass). We applied ; the number of coughs was assumed to follow a Poisson distribution adjusted for tachyphylaxis evoked by repeat inhalations of the same capsaicin dose. The capsaicin-evoked cough response curve was assumed to follow a sigmoid shape in which the maximum response was denoted as E max and the capsaicin dose inducing half-maximal response (ED 50 ). The effect of continuous and categorical covariates were investigated, including age, sex, body mass index, disease state (healthy or asthmatic), atopy (atopic or nonatopic), predicted FEV 1 , cough frequency, serum IgE measurement, blood eosinophil count, FENO value, methacholine PC 20 , and ACQ and LCQ score. The pharmacodynamic model was used to simulate typical dose-response curves for significant covariates. Finally, we also calculated the traditional concentration of capsaicin inducing at least 2 coughs (C2) and C5 end points from our challenges to explore the differences between healthy control subjects and asthmatic patients and the effects of the same continuous and categorical covariates. See the Methods section in this article's Online Repository for full details of the nonlinear model and C2/C5 analyses.
RESULTS Subjects
Ninety-seven asthmatic patients and 47 healthy volunteers were recruited and completed all visits; see Fig E1 in this article's Online Repository at www.jacionline.org for exclusions, withdrawals, and missing data. Asthmatic patients and healthy volunteers were well matched for sex, body mass index, and smoking history, but asthmatic patients were significantly younger and had slightly reduced lung volumes compared with healthy volunteers (Table I) . Asthmatic patients had low cough frequencies, but these were statistically higher than those in healthy volunteers.
Asthmatic patients' symptoms were well or partly controlled (Table II) . Almost 50% were steroid naive, and one third were receiving a low dose of inhaled steroid. The majority were atopic based on 1 or more positive skin prick test responses to a common aeroallergen and exhibited bronchial hyperresponsiveness to methacholine.
Application of the pharmacodynamic model
The model parameters are described in Table III IVand Fig 1, A) . Specifically, asthmatic patients had a 71% lower ED 50 value (P 5 .0008) than healthy volunteers, with no difference in ED 50 values between atopic and nonatopic asthmatic patients. Nonatopic asthmatic patients had a 46% higher E max value (P 5 .003) compared with healthy volunteers, but atopic asthmatic patients had a 21% lower E max value (P 5 .04) than nonatopic asthmatic patients (Tables III and IV and Fig 1, C) . In addition, female sex increased E max values by 27% (P 5 .006) and decreased ED 50 values by 65% (P 5 .0001; Tables III and  IV and Fig 1, B) .
The interaction between these characteristics was simulated to create the typical dose-response curves shown in Fig 2. Healthy male subjects had the lowest cough responses, whereas female nonatopic asthmatic patients had the highest cough responses to capsaicin. Capsaicin-evoked cough responses are associated with cough frequency and asthma control
Higher 24-hour cough frequency (coughs per hour) was associated with increased E max values (P 5 .006; Fig 3, A, and Table III) . Specifically, for every unit that cough frequency increased, E max values increase by approximately 5%. Also, higher ACQ scores were associated with lower ED 50 values (P 5 .02; Fig 3, B, and Table III ). The median ACQ score in the studied asthmatic population was 0.71; if, for example, this score increased by 1 unit (1.71), the ED 50 value decreased by 48%. Finally, higher IgE levels were associated with an increase in ED 50 values (P 5 .01; Fig 3 , C, and Table III ). For every unit that IgE increased, ED 50 increased approximately by 0.15%. The effect of these continuous covariates on the simulated dose-response curves is shown in Fig 4. Other covariates, such as age, body mass index, FEV 1 percent predicted, PC 20 and FENO values, serum eosinophil counts, and LCQ scores had no significant influence on model parameters (E max , ED 50 , and g). There was a nonsignificant trend (P 5 .09) that asthmatic patients receiving steroids had a lower maximal number of coughs (E max ) compared with asthmatic patients not receiving steroids, but no differences were observed for ED 50 or g values. In addition, the magnitude of the steroid dose (in subjects receiving steroids) did not affect the model parameters.
Termination of the cough challenge
At higher doses of capsaicin, increasing numbers of patients elected to terminate the challenge (se Figs E2 and E4, A, in this article's Online Repository at www.jacionline.org). The most important determinant of whether a subject was likely to terminate the challenge at a given dose level was the total cumulative number of coughs up to the maximum tolerated dose (see Fig E4, B) . When subjects reached an approximate threshold of 40 to 60 cumulative coughs, they tended to terminate no matter whether this threshold was reached at a low or high capsaicin dose (see Fig E4, B) .
Safety of full-dose capsaicin challenge
Transient bronchoconstriction after inhaling capsaicin has been reported in patients with asthma. 19 In this study there was no significant bronchoconstriction after inhaling high-dose capsaicin; the median change in percentage FEV 1 after capsaicin challenge was 21.7% (interquartile range, 0.8% to 24.3%). However, 1 subject did decrease their FEV 1 by 54% and coughed a total of 38 times at a low concentration of capsaicin (15.6 mmol/L). The subject received 4 inhalations of salbutamol (100 mg), after which FEV 1 improved to baseline. A, healthy volunteers versus asthmatic patients; B, male versus female subject; C, atopic vs nonatopic asthmatic patients. Average number of coughs (y-axis) is plotted against capsaicin dose (x-axis). Bars and red lines represent the observed and model-predicted number of coughs, respectively, averaged across all subjects in a specific covariate subpopulation and all inhalations at a given capsaicin dose level. The number of subjects in each subpopulation subjected to at least 1 inhalation at a given dose level are also reported inside (or above) each bar.
Exploratory analysis of C2 and C5 end points
Asthmatic patients demonstrated significantly lower C2 and C5 than healthy control subjects (P 5 .002 and P 5 .013, respectively; see Table E1 in this article's Online Repository at www.jacionline.org). However, there was substantial variability between subjects and overlap between the 2 groups for C2 and C5; 42% of healthy volunteers and 30% of asthmatic patients did not have a measureable C5 (see Fig E5 in this article's Online Repository at www.jacionline.org). Furthermore, multiple linear regression models did not show significant relationships between covariates identified as important in the nonlinear model; only log ACQ scores were related to log C5 (see the Results section in this article's Online Repository at www.jacionline.org for full details).
DISCUSSION
This study is the first to show evidence of heightened capsaicinevoked cough responses and thus neuronal dysfunction in patients with stable mild-to-moderate asthma. These changes in capsaicin responses can only be fully appreciated by extending cough challenge beyond the standard C5 end point and with implementation of population pharmacodynamic modeling to provide individual estimates of ED 50 and E max values. Using this methodology, we showed that asthmatic patients, when compared with healthy volunteers, started to cough at lower capsaicin doses (lower ED 50 values) and had greater maximal cough responses (higher E max values), both of which are indicative of increased excitability of the neuronal pathways controlling cough. Notably, both sex and atopic status significantly influenced cough responses, with nonatopic female asthmatic patients exhibiting the greatest degree of neuronal dysfunction. Importantly, measures of inflammation, such as FENO, bronchial hyperresponsiveness (PC 20 ), or lung function, did not influence E max or ED 50 values, suggesting this neuronal dysfunction was independent of airway inflammation and bronchial hyperresponsiveness.
It is difficult to directly compare these results with other studies that have used the standard C5 end point because the patients' demographics are very different from those in our study. Doherty et al 10 compared C5 values in a group of asthmatic patients and healthy volunteers and demonstrated an increased sensitivity to capsaicin. However, subjects in that study were older and had more severe asthma (mean FEV 1 percent predicted [71%], all receiving inhaled steroids, 21% receiving an inhaled anticholinergic agent, and 8% receiving theophylline), and only 43% were nonsmokers. Fujimura et al 13 evaluated just 18 asthmatic patients with worse lung function (mean FEV 1 percent predicted, 67%) yet found no difference in C5 from healthy control subjects. It was striking that we demonstrated highly statistically significant differences in capsaicin-evoked responses in a cohort of younger patients who were all nonsmokers with good lung function, and almost half were steroid naive. Our exploratory analysis extrapolating C2 and C5 from our challenge protocol shows these end points are statistically different in asthmatic patients compared with healthy volunteers. However, unlike E max and ED 50 values, C2 and C5 did not relate to any of the clinical features of asthma apart from control, not even with cough frequency, which might be expected. This suggests C2 and C5 are not only less powerful than E max and ED 50 but also do not represent the underlying mechanisms important in different asthma phenotypes.
Sex differences in evoked cough have not previously been specifically described in asthmatic patients but have been repeatedly shown in both healthy volunteers and patients with chronic cough, with female patients demonstrating heightened responses compared with male patints. 14, 20 However, the observation that patients with nonatopic asthma have exaggerated responses (increased E max values) compared with those with atopic asthma is a novel finding that was unexpected and requires further exploration. Consistent with this, lower IgE levels were associated with reduced threshold for capsaicin-evoked coughs (reduced ED 50 values). The combined effects of sex and atopy suggest that the highest cough responses and thus the greatest degree of neuronal dysfunction were exhibited by female nonatopic asthmatic patients. By comparison, atopic male asthmatic patients displayed the lowest levels of dysfunction among asthmatic patients, and healthy male subjects had the lowest responses overall (Fig 2) . Our findings could help explain the results of a cluster analysis of asthmatic patients, highlighting 2 discordant groups in which symptoms did not match the degree of airway inflammation. 21 Interestingly, excessive symptoms were observed in the predominantly female cluster with fewer atopic subjects, whereas low symptoms were observed in the cluster who were predominantly male and atopic. Therefore we speculate that neuronal dysfunction could explain the discordance between such clinical phenotypes of asthma.
We also found capsaicin-evoked cough responses were relevant to the clinical manifestations of asthma. Poorer asthma control, as measured by ACQ scores, was associated with lower cough thresholds (ED 50 ), and higher 24-hour objective cough frequencies were associated with higher maximal cough responses (E max ). It is interesting to speculate that these differences in capsaicin-evoked cough responses might represent different mechanisms of neuronal dysfunction in either the peripheral or central nervous system. Moreover, these changes in cough reflex responses might also provide a surrogate for changes in other populations of airway nerves responsible for mediating symptoms that are less easily quantified, such as chest tightness and breathlessness.
Nerve fibers have a maximum frequency of action potential firing, as determined based on the rate of membrane repolarization (refractory period). However, the threshold for action potential generation can be decreased by changes in the membrane resting potential or ion channels at the nerve terminal per hour) ; B, low versus high ACQ score; C, low versus high IgE levels (in kilounits per liter). Average number of coughs (y-axis) is plotted against capsaicin dose (x-axis). Bars and red lines represent observed and model-predicted number of coughs, respectively, averaged across all subjects in a specific covariate subpopulation and all inhalations at a given capsaicin dose level. The number of subjects in each subpopulation subjected to at least 1 inhalation at a given dose level are also reported inside (or above) each bar.
(eg, increased expression, membrane insertion, and conformational changes). 22 Such changes can be induced by a range of inflammatory mediators, including cytokines, chemokines, and growth factors. Ad fibers can also become responsive to capsaicin after airway exposure to allergen and cigarette smoke, with novel gene expression of TRPV1, which is known as phenotypic switching. 23 This can potentially affect both ED 50 and E max values; the membrane depolarization threshold can be reached more easily, causing a leftward shift (lower ED 50 value), but in addition, the usual E max ceiling can be exceeded by the recruitment of a newly capsaicin-responsive nerve fiber subtype. Although changes to the afferent fibers innervating the airways are the most plausible explanation for the exaggerated cough responses we have observed in asthmatic patients, modification of action potentials at the first synapse in the brainstem and in the cortical and subcortical pathways could also occur. Processes analogous to central sensitization 24, 25 and/or loss of descending neural inhibitory control mechanisms, as described in chronic pain states, have the potential to produce similar effects. 26 However, these possible mechanisms are largely unexplored in asthmatic patients.
Asthma is generally considered a chronic inflammatory disease, with the role of airway innervation or even the contribution of neuroimmune interactions rarely investigated. Cytokines, chemokines, growth factors, and lipids released by immune cells have all been shown to induce profound changes in the activity and sensitivity of peripheral nerve terminals in the somatosensory system and have the potential to explain the changes in neuronal function that we have observed. 27, 28 In particular, growth factors, such as nerve growth factor and brain-derived neurotrophic factor, have the potential to induce long-term qualitative changes to a range of stimuli to which nerves respond, and this has been demonstrated in an animal model of allergic asthma. 23 However, the most heightened neuronal dysfunction was observed in patients with nonatopic asthma and perhaps low T H 2 disease. Therefore neuronal dysfunction has the potential to provide insights into mechanisms underlying this phenotype and suggest new treatment targets.
There are some limitations to this study. First, the study population was young, mainly atopic, and predominantly steroid naive. It is currently unclear how generalizable these findings are to other age groups with more severe disease. Second, apart from measuring serum eosinophil counts, IgE levels, and FENO values, we did not make direct measures of airway inflammation and hence were not able to investigate whether these influenced capsaicin-evoked responses. Finally, we chose capsaicin because it is the most widely used cough challenge agent, and it is with this methodology that we developed the previous pharmacodynamic model. 14 However, it remains to be seen whether other challenge agents, such as citric acid, provide different results and hence novel insights into cough mechanisms.
In conclusion, these data are consistent with the concept that neuronal dysfunction is a feature of asthma, even in those with mild stable disease. Therefore assessing capsaicin-evoked cough responses might provide an additional tool in phenotyping asthma and identifying those in whom this mechanism might be most prominent. Although our data suggest neuronal dysfunction seems to be independent of indirect measures of airway inflammation, studies are required to directly assess the effects of airway inflammation on capsaicin-evoked coughs. If neuronal dysfunction is truly independent of airway inflammation, it is unlikely to be addressed by current therapies. Hence novel neuromodulatory treatments could be a useful adjunct in treating asthma and perhaps most effective in nonatopic patients.
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Key messages
d Using a novel challenge methodology and pharmacodynamic modeling, we have demonstrated that patients with mild-to-moderate asthma have a heightened cough response to inhaled capsaicin that is most evident in female nonatopic subjects. Questionnaires. Subjects completed the full ACQ and LCQ, as described previously. Subjects were also classified on the basis of Global Initiative for Asthma categories as having well-controlled, partly controlled, not well-controlled asthma. The latter group were excluded from the study.
Cough monitoring. Objective 24-hour cough monitoring was performed with the VitaloJAK cough recorder (VitaloJAK, Vitalograph). Twenty-four-hour ambulatory cough sound recordings were performed with a custom-built validated recording device and microphone. Briefly, this consists of a digital data logger recording sounds at a sample rate of 8 kHz, with 16-bit resolution and in wav format, which is a commonly used uncompressed sound file format. Recordings were transferred to a personal computer; silences and background noise were removed by using validated, custom-written software
E1
; and cough sounds were counted by using an audio editing package (Audition version 3; Adobe Systems, San Jose, Calif). The number of coughs was expressed as coughs per hour.
Blood sampling. Two samples of blood tests were taken from asthmatic patients for full blood counts (to assess serum eosinophils) and total IgE measurements.
Skin prick testing. Atopy was defined by the presence of at least 1 positive skin prick test response (> _3 mm) to commonly inhaled aeroallergens. The following were tested:
1. house dust mite; 2. mixed molds I: Alternaria tenuis, Botrytis cinerea, Cladosporium herbarum, Curvularia lunata, Fusarium moniliforme, and Helminthosporium halodes; 3. mixed molds II: Aspergillus fumigatus, Mucor mucedo, Penicillium notatum, Pullularia pullulans, Rhizopus nigricans, and Serpula lacrymans; 4. grass mix: Yorkshire fog/velvet grass, cocksfoot, rye grass, timothy, meadow grass/Kentucky blue grass, and tall fescue/meadow fescue; 5. tree mix (mid blossoming): birch, beech, oak, and plane; 6. cat; 7. dog; 8. histamine (positive control); and 9. saline (negative control).
Bronchial hyperresponsiveness testing. Methacholine challenge was performed to assess bronchial hyperresponsiveness by using the 2-minute tidal breathing methodology, according to standard ATS guidelines. Any inhaled medications were withdrawn per ATS guidelines.
E2
The concentration causing a 20% decrease from baseline FEV 1 in response to methacholine (PC 20 ) was documented.
Capsaicin cough challenge. A full-dose capsaicin-evoked cough challenge was performed by using the methodology described previously E3 with a nebulizer pot (Model 646, Devilbiss Healthcare) and dosimeter (KoKo Dosimeter; Ferraris, Hertford, United Kingdom). Two milliliters of capsaicin solution at 1000 mmol/L (Stockport Pharmaceuticals, Stockport, United Kingdom) was serially diluted with 2 mL of saline (0.9%) to create solutions of concentrations of 500, 250, 125, 62.5, 31.3, 15.6, 7.8, 3.95, 1.95, 0.98, and 0.48 mmol/L. Spirometry was performed, and a cough monitor (VitaloJAK) was attached to aid in manual verification of capsaicin-evoked coughs. Calibrated Devilbiss 646 nebulizer pots were fitted with an inspiratory flow limiter and connected to a dosimeter (KoKo) at a pressure of 30 psi to ensure accurate dosing was achieved, which emitted between 10 to 12 mL per actuation. The full-dose capsaicin-evoked cough challenge involved administering 4 inhalations 30 seconds apart of doubling doses of capsaicin, starting from 0.48 to 1000 mmol/L.
After each inhalation, the number of coughs in the first 15 seconds was recorded and later verified. The highest total number of coughs evoked at any dose of capsaicin is denoted as E max , and the dose evoking half this response is denoted as ED 50 . To explore how these novel end points compare with traditional cough challenge end points, we also calculated the concentration of capsaicin evoking at least 2 and 5 coughs (ie, C2 and C5). Our challenge methodology is slightly different from the traditional challenge because 4 inhalations rather than 1 inhalation are performed at each concentration. Therefore to calculate C2 and C5, we simply used the number of coughs evoked by the first of these 4 inhalations. If subjects did not cough 2 or 5 times during the whole challenge, then for the purposes of this analysis, a value of 2000 mmol/L was assigned. Spirometry was performed after challenge, and if there was a greater than 10% decrease in FEV 1 compared with baseline or subjects complained of any chest symptoms, then 4 puffs of salbutamol (100 mg) was administered through a spacer. The challenge ended when the patient reached the final concentration of capsaicin or the maximal tolerated dose.
Nonlinear mixed-effects modeling in detail Population pharmacodynamic model: Model structure. Population pharmacodynamic modeling was performed with the nonlinear mixed-effects modeling software NONMEM (version 7.3, ICON Development Solutions) and the Laplace estimation method.
E4,E5
Goodness-of-fit plots, statistical analyses, and simulations were performed in Matlab R2014a (MathWorks). In total, 6606 observations (verified cough measurements) from 144 subjects were analyzed for development of the population dose-response model. The response variable (number of coughs) is discrete (count data) and was assumed to follow the Poisson distribution (Equation E1) E6 :
where P(Y i 5 n) is the probability that individual i is having n (50,1,2,.) number of coughs per interval of time, and l i is the individual mean count response. The individual mean count response (l i ) is expressed as a function of capsaicin dose according to Equation E2:
where E 0 represents the mean cough count at baseline (placebo), Emax i is the maximum number of coughs in individual i, ED50 i is the capsaicin dose that induces half of the maximum effect in individual i, D is the administered capsaicin dose, and g i is the Hill factor that controls the steepness of the dose-response sigmoidal curve in individual i. Interindividual variability random effect terms were assigned on model parameters (E max , ED 50 , and g) by using an exponential relationship (Equation E3):
where u Emax is the typical E max parameter value in the population, and h iEmax is the E max interindividual variability random effect parameter, which is assumed to be normally distributed with mean zero and variance as follows:
Tachyphylaxis effect. In a previous study E3 it was identified that incorporation of a tachyphylaxis parameter substantially improved the description of the observed cough response data after serial capsaicin inhalations. Therefore in the current work we carefully examined data with regard to the occurrence of a tachyphylaxis pattern between consecutive inhalations of the same capsaicin dose. If such a pattern was apparent, we subsequently incorporated a tachyphylaxis parameter (K) in the model (similar to Hilton et al E3 ) according to Equation E4 and investigated the extent that model fit was improved:
where j 5 1,2,3; Emax i (j) and Emax i (j11) correspond to the individual E max value referring to the jth and j11th inhalation, respectively, of the same capsaicin dose, and K is a positive real number. The above equation implies that tachyphylaxis (reduced response) occurs between consecutive inhalations of the same capsaicin dose.
Covariate model building. After development of the base population pharmacodynamic model, a covariate analysis was performed in an effort to explain some of the observed interindividual variability in cough responses. Both continuous and categorical covariates were investigated in the covariate model-building procedure, including age, sex, body mass index, disease state (health or asthma), atopy (atopic or nonatopic), predicted FEV 1 , cough frequency from the monitoring of spontaneous cough, IgE levels, eosinophil levels, FENO levels, and ACQ and LCQ scores. Empiric Bayes estimates of the interindividual variability random effects (h i ) from the base model (without any covariates) were used for an initial screening of the covariates, given a low h shrinkage. E7 Subsequently, covariate model building was performed with a stepwise forward inclusion-backwards deletion procedure in which covariate selection is guided at each step by likelihood ratio test between nested models.
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A bootstrapping procedure (n 5 1000) was performed with PsN 3.7.6 (Perl-speaks-NONMEM) E10 for the final model to evaluate the robustness of the parameter estimates and provide nonparametric 95% CIs. A covariate effect was retained in the final model only if all of the following conditions applied: (1) the direction of the covariate effect was physiologically/mechanistically plausible based on our understanding of the underlying system and prior knowledge; (2) removal of the covariate caused the model to be inferior at the .05 statistical level (assessed by using a likelihood ratio test); and (3) the bootstrap-obtained nonparametric 95% CI for the covariate effect did not include zero.
Investigation of termination of the cough challenge.
Because of the nature of the ascending-dose capsaicin challenge, it is expected that a substantial number of participants will elect to terminate the challenge before reaching the maximum capsaicin dose. Possible reasons for terminating the challenge include discomfort because of excessive coughing or sensations of heat/stinging/burning in the throat at higher concentrations of capsaicin. Termination of the cough challenge results in missing data at higher capsaicin concentrations, which might have implications for the modeling strategy/ methodology. Therefore an exploratory statistical and graphical analysis of the raw cough response data was performed to further understand the reasons for termination of the cough challenge.
Linear regression modeling of C2 and C5
To explore the utility of C2 and C5, we compared log base 10-transformed values in health and disease using an independent t test. To see how these end points performed compared with E max and ED 50 , we carried out linear regression modeling to test whether the features of asthma found to influence E max and ED 50 similarly influenced log C2 and log C5.
RESULTS

Detailed results of modeling
Population pharmacodynamic model. The parameter estimation process and covariance step for the final population pharmacodynamic model (including covariates) converged successfully under the Laplace estimation method and a requested precision of more than 3 significant digits in the parameter estimates. The parameter estimates of the final population model are reported in Table III , together with the bootstrap results and 95% nonparametric CIs around these estimates. All model parameters (including both fixed and random effects) were estimated with adequate precision (see Table III ). The average cough response at baseline, referred as E 0 , was estimated to be only 0.06, indicating that cough response is very rare when the capsaicin dose is zero.
Tachyphylaxis effect. A tachyphylaxis pattern was apparent after examination of the raw cough response data because the magnitude of response (number of coughs) was decreased with consecutive inhalations of the same capsaicin dose. Similar to the tachyphylaxis pattern previously reported, E3 this was apparent in all the capsaicin dose levels apart from the 2 low doses (0.48 and 0.98 mmol/L) at which cough responses were minimal, and the highest dose (1000 mmol/L), at which the sample size was small, because many subjects had terminated the challenge before this dose. Incorporation of a tachyphylaxis parameter (K) substantially improved the model fit and model diagnostics and was retained in the final model. More specifically, incorporation of this parameter in the model decreased the objective function value (22 log-likelihood) by 181 units. The tachyphylaxis parameter (K) was estimated to be 0.142 (see Table III ), which practically means that the E max value decreases approximately by 13% (calculated as 12e 2K 5 0.13) for any capsaicin inhalation preceded by another inhalation at the same dose level. This is in agreement with our previous work, in which the decrease in E max value because of tachyphylaxis was estimated to be around 15% in another population. E3 This replication provides additional confidence that the model adequately captures the true quantitative effect of the underlying tachyphylaxis physiologic mechanism on the observed cough response.
Interindividual variability random effect terms were assigned on the following structural model parameters: E max , ED 50 , and g. The estimates of these variability terms (see Table III ) clearly indicated that the magnitude of population variability in ED 50 values was vast (coefficient of variation, 282%) and in particular higher than the population variability in E max values (coefficient of variation, 40%). The magnitude of h shrinkage in the final population model was 19%, 3%, and 32% for the interindividual variability terms of E max , ED 50 , and g, respectively.
The observed raw dose-response data together with the model fit are illustrated in Fig E2, in which it is apparent that the developed model provided a very good fit to the observed data. The pattern of decreased average number of coughs observed in the last few high doses of capsaicin did not represent a true dose-response relationship but was due to the subset of subjects who reached these high dose levels having substantially lower E max and higher ED 50 values (ie, they had overall reduced cough responses to capsaicin).
The model fit to the observed dose-response data at the individual level is illustrated in Fig E3 for 16 representative subjects. It is clearly demonstrated that the observed dose-response relationship is completely different between subjects. For example, some subjects had a substantial number of coughs relatively early in the ascending-dose challenge (eg, ID 5 6), whereas others had only a limited number of coughs, even at the highest dose levels (eg, ID 5 31 and ID 5 300). However, it is apparent from Fig E3 that the developed mixed-effects population model is flexible enough to very accurately capture all these patterns of different dose-response relationships across different subjects.
Identification of covariate effects. The final population model included the influences of both categorical and continuous covariates: disease state (health or asthma), sex, atopy (atopic or nonatopic), cough frequency, ACQ questionnaire score, and IgE levels. Inclusion of these covariates resulted in a substantial improvement of the model because they decreased the objective function (22 log-likelihood) by approximately 68 units compared with the objective function of the base model (model with no covariates). All the covariates retained in the final model offered additional and at least partly unique information because removal of each of the covariates causes the model to be statistically inferior. The level of statistical evidence regarding each covariate (increase in objective function after removing each covariate from the final model and the corresponding likelihood ratio test P value) is presented in the legend of Table III . In addition, the bootstrap-obtained nonparametric 95% CIs regarding all the covariate effects in the final model are reported in Table III , where it is apparent that they do not include zero. The equations that described the typical values of the model parameters, including covariate effects, are listed below:
ðIgE2200ÞÞ$e GROU$u 12 $ðACQ20:71Þ ; where GROU is a dummy variable that takes a value of 1 for asthmatic patients and 0 for healthy volunteers; GEN is a dummy variable that takes a value of 1 for female and 0 for male subjects; ATO is a dummy variable that takes the value 1 for atopic asthmatic and 0 for nonatopic asthmatic patients; Cfreq is the spontaneous cough frequency (coughs per hour) over 24 hours; IgE is the IgE level measurement (in kilounits per liter); and ACQ is the ACQ questionnaire score.
For all continuous covariates in the model (Cfreq, IgE, and ACQ), covariate effects were centered around the median population values in the analyzed data set (0.75, 200, and 0.71, respectively) to increase model stability and allow parameter interpretation with respect to a typical/reference subject. It should be noted that Cfreq values were missing for 7 of the 144 studied subjects, and therefore these values were imputed with the population median. This imputation did not have an effect on the results because when these subjects were excluded from the analysis, all the parameter estimates (including all covariate effects) were comparable. Figs 1 and 3 show the model fit to the observed dose-response data stratified by the significant categorical and continuous model covariates, respectively. It is apparent from these figures that substantially different dose-response patterns were observed across the different covariate subpopulations (eg, healthy volunteers vs asthmatic patients and male vs female subjects). However, the developed covariate-incorporated population model very accurately described the observed dose-response relationships within each of these subpopulations.
Model-simulated typical dose-response curves for subjects with different population characteristics are presented in Fig 2 to illustrate the effect of the model-incorporated categorical covariates on the dose-response relationship. Similarly, the effect of the model-incorporated continuous covariates on the simulated dose-response curves is shown in Fig 4. All the significant covariate effects (see Table III and Figs 1-4) are described in the main article. It should be noted that although it was possible in the current work to explain part of the observed variability in cough response through incorporation of several covariates, the extent of unexplained interindividual variability remains substantial.
Investigation of termination of the cough challenge. An exploratory analysis of the raw cough response data with regard to termination of the challenge is shown in Fig E4. The number of subjects who performed at least 1 inhalation at a given dose level decreased as the capsaicin dose increased (Fig E4, A) . The most important determinant of termination of the challenge at a given dose level was the total number of coughs in the entire challenge up to that specific dose. Fig E4, B, shows that subjects who terminated the challenge at a given dose level had substantially more coughs in the challenge up to this dose compared with subjects who continued to the next capsaicin dose level; bootstrap 95% CIs (using bootci in MATLAB) indicated a statistically significant difference in the number of coughs for the majority of the capsaicin dose levels. Fig E4, B, suggests that when subjects reach a threshold of approximately 40 to 60 coughs, they tend to terminate the challenge, irrespective of the dose of capsaicin at which this occurs.
Although the missing data mechanism (termination of the challenge) was not independent of the response values, it depends on them only through the observed components of the response (number of coughs up the point of dropout). Therefore valid estimation-based inferences could be obtained with the maximum likelihood mixed-effects modeling approach, without the need to simultaneously develop a model for the missing data. E11 The development of a dropout model for the capsaicin cough challenge, although not necessary for analysis of this data set, represents a significant task. This is currently in progress because it will inform the design of future clinical studies and allow the performance of clinical trial simulation.
Exploratory analysis of C2 and C5 end points
Comparison of healthy volunteers and asthmatic patients. As shown in Table E1 , asthmatic patients demonstrated significantly lower C2 and C5 (ie, were more sensitive to capsaicin) than healthy volunteers. However, as shown in Fig E5, there was substantial variability in these end points and overlap between health and disease. Moreover, many subjects in both groups did not achieve measureable C5, particularly for the C5 end point (42% of healthy volunteers and 30% of asthmatic patients).
Predictors of C2 responses. Analyzing healthy volunteers and asthma data combined in the simplest model, both sex (P < .001) and disease group (P < .001) significantly predicted log C2, explaining 17.5% of the variance; female subjects were more sensitive to capsaicin than male subjects, and asthmatic patients were more sensitive than healthy volunteers. However, when the predictors of capsaicin responses found to be significant in our nonlinear modeling approach (disease group, sex, atopic status, log cough frequency, log total IgE level, and log ACQ score) were introduced in the linear regression model, none significantly predicted log C2.
Predictors of C5 responses. Again, in the simplest model both sex (P 5 .002) and disease group (P 5 .002) significantly predicted log C5, explaining 11.2% of the variance. When the predictors of capsaicin responses found to be significant in our nonlinear modeling approach were introduced in the linear regression model, only log ACQ score significantly predicted log C5 (b 5 20.8, P 5 .012; ie, worse asthma control was associated with a lower C5 value).
FIG E2.
Model fit to the observed dose-response data. The average number of coughs (y-axis) is plotted against the capsaicin dose (x-axis). Bars and the red line represent the observed and model-predicted number of coughs, respectively, averaged across all subjects and inhalations at a given capsaicin dose level. The number of subjects subjected to at least 1 inhalation at a given dose level is also reported inside (or above) each bar. The number of coughs (y-axis) averaged across all inhalations at a given capsaicin dose level for a given subject is plotted against the capsaicin dose (x-axis).
FIG E4.
Investigation of the challenge termination pattern in the raw cough response data. A, Number of subjects (y-axis) performing at least 1 inhalation at a given dose level is plotted against the capsaicin dose (x-axis). B, Average number of total coughs in the challenge (y-axis) up to a given capsaicin dose (x-axis) for subjects who do or do not terminate the challenge after this specific dose. For example, the 4 subjects who dropped out after inhaling the 7.81 mmol/L dose (third marker from the left) had, on average, of 43 coughs up to this point of the challenge; the 137 subjects that did not drop out and continued to the higher dose level had, on average, only 13 coughs up to this point of the challenge. Markers highlighted with an asterisk indicate a statistically significant difference in total coughs between the dropout and nondropout groups at a given dose level. 
